Live Webinar

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Hosted by AJMC and Targeted Oncology

-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Logo Image
Opinion|Videos|January 17, 2025

Sequencing Considerations in Relapsed/Refractory CLL

Panelists discuss how strategic sequencing decisions in frontline CLL therapy, informed by new evidence from the Rhodes et al. ASH 2024 study, have downstream implications for managing treatment options in the relapsed/refractory setting.

Episodes in this series

Video content above is prompted by the following:

  • What sequencing considerations influence your choice of upfront therapy for chronic lymphocytic leukemia (CLL), and how do these decisions shape the selection of treatments in the relapsed/refractoryCLL setting?
  • How does the treatment sequencing study in CLL/SLL by Rhodes and colleagues, presented at the 2024 American Society of Hematology annual meeting, influence your clinical approach?

Related Content